Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKerry Regulatory News (KYGA)

Share Price Information for Kerry (KYGA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 77.90
Bid: 0.00
Ask: 80.80
Change: 1.10 (1.43%)
Spread: 1.80 (2.278%)
Open: 77.70
High: 78.10
Low: 76.80
Prev. Close: 76.80
KYGA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Kerry to acquire Lactase Enzymes Business

12 Dec 2023 16:13

RNS Number : 5363W
Kerry Group PLC
12 December 2023

12 December 2023

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP

Kerry to acquire Lactase Enzymes Business

Kerry Group plc ("Kerry"), the global taste & nutrition company, announces it has entered into a definitive agreement to acquire part of the global lactase enzyme business of Chr. Hansen Holding A/S ("Chr. Hansen") and Novozymes A/S ("Novozymes") (together the "Lactase Enzymes Business") on a carve out basis¹. This acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger approval process.

The Lactase Enzymes Business which includes NOLA® Products, further enhances Kerry's biotechnology solutions capability following the acquisitions of c-LEcta and Enmex². This acquisition adds enzyme technology which helps create lactose-free and sugar reduced dairy products, while preserving their authentic clean taste. Global demand for lactase is being driven by increased awareness of lactose intolerance, while many consumers are also choosing lactose-free for lifestyle and health reasons.

The Lactase Enzymes Business had attributable revenue of approximately ?40m in 2022 with sales in over 50 countries. Total consideration is ?150m subject to routine closing adjustments, with the acquisition expected to close in the first half of 2024.

¹ Acquisition comprises certain trade and assets of Chr. Hansen's global lactase enzyme business and 100% of the share capital of Nuocheng Trillion Food (Tianjin) Co., Ltd, a Chinese subsidiary of Novozymes.

² Acquisition of c-LEcta GmbH completed in March 2022 and Enmex S.A. de C.V. in December 2021.

ENDS

About Kerry

Kerry is a world leading taste and nutrition partner for the food, beverage and pharmaceutical markets. We innovate with our customers to create great tasting products, with improved nutrition and functionality, while ensuring better impact for the planet. Our leading consumer insights, global RD&A team of 1,100+ food scientists and extensive global footprint enable us to solve our customers' complex challenges with differentiated solutions. At Kerry, we are driven to be our customers' most valued partner, creating a world of sustainable nutrition, and to reach over 2 billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerry.com.

CONTACT INFORMATION

Investor Relations

Marguerite Larkin, Chief Financial Officer

+353 66 7182292 | investorrelations@kerry.ie

William Lynch, Head of Investor Relations

+353 66 7182292 | investorrelations@kerry.ie

Media

Catherine Keogh, Chief Corporate Affairs & Brand Officer

+353 45 930188 | corpaffairs@kerry.com

Website

www.kerry.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ACQBLBDDDBBDGXD
Date   Source Headline
15th May 20205:11 pmRNSHolding(s) in Company
7th May 20206:17 pmRNSHolding(s) in Company
1st May 20209:12 amRNSTotal Voting Rights
30th Apr 20204:55 pmRNSResult of AGM
30th Apr 20204:40 pmRNSDirectorate Change
30th Apr 20207:00 amRNSQ1 Interim Management Statement 2020
17th Apr 202012:14 pmRNSRevised Arrangements for the AGM
1st Apr 20209:28 amRNSTotal Voting Rights
30th Mar 202012:30 pmRNSAnnual Report and AGM Notice
6th Mar 20204:36 pmRNSDirector/PDMR Shareholding
6th Mar 20204:33 pmRNSDirector/PDMR Shareholding
2nd Mar 202010:23 amRNSTotal Voting Rights
18th Feb 20207:00 amRNSPreliminary Statement of Results 2019
17th Feb 202010:25 amRNSNotice of Results and AGM
3rd Feb 202012:08 pmRNSBlock listing 6 Monthly Return
3rd Feb 202010:18 amRNSTotal Voting Rights
2nd Jan 202012:48 pmRNSTotal Voting Rights
2nd Dec 20192:41 pmRNSTotal Voting Rights
21st Nov 201911:09 amRNSHolding(s) in Company
6th Nov 20197:00 amRNSQ3 Interim Management Statement
1st Nov 201911:05 amRNSTotal Voting Rights
1st Oct 201910:44 amRNSTotal Voting Rights
26th Sep 20194:24 pmRNSHolding(s) in Company
2nd Sep 20192:16 pmRNSTotal Voting Rights
8th Aug 20197:00 amRNSInterim Management Report 30 June 2019
1st Aug 20192:36 pmRNSTotal Voting Rights
1st Jul 20192:36 pmRNSBlock listing Interim Review
1st Jul 20192:26 pmRNSTotal Voting Rights
4th Jun 20193:07 pmRNSTotal Voting Rights
30th May 20192:26 pmRNSTR-1 Notification of Major Holdings
3rd May 20199:00 amRNSResult of AGM
2nd May 20197:00 amRNSQ1 2019 Interim Management Statement
1st May 201912:57 pmRNSTotal Voting Rights
1st Apr 201912:35 pmRNSTotal Voting Rights
28th Mar 201911:56 amRNSAnnual Financial Report
8th Mar 20192:15 pmRNSDirector/PDMR Shareholding
8th Mar 20192:14 pmRNSDirector/PDMR Shareholding
1st Mar 201912:12 pmRNSTotal Voting Rights
19th Feb 20197:00 amRNSPreliminary Statement of Results 2018
1st Feb 201910:34 amRNSTotal Voting Rights
2nd Jan 20192:44 pmRNSBlock listing Interim Review
2nd Jan 20192:34 pmRNSTotal Voting Rights
28th Dec 201812:00 pmRNSDirectorate Change
14th Dec 20187:00 amRNSKerry announces two further strategic acquisitions
3rd Dec 20182:30 pmRNSTotal Voting Rights
16th Nov 201810:12 amRNSDirector/PDMR Shareholding
12th Nov 20183:44 pmRNSDirector/PDMR Shareholding
7th Nov 20187:00 amRNSQ3 Interim Management Statement
25th Oct 20187:00 amRNSKerry announces further strategic acquisitions
11th Oct 201811:08 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.